Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters

Database
Language
Publication year range
1.
Blood ; 143(2): 152-165, 2024 Jan 11.
Article in English | MEDLINE | ID: mdl-37832030

ABSTRACT

ABSTRACT: Plasmablastic lymphoma (PBL) is a rare and aggressive non-Hodgkin lymphoma associated with immunodeficiency, characterized by uncertain treatment approaches and an unfavorable prognosis. We conducted a multicenter, international, retrospective cohort study, aiming to characterize the clinical features, risk factors, and outcomes of patients with PBL. Data were collected from 22 institutions across 4 countries regarding patients diagnosed with PBL between 1 January 1999 and 31 December 2020. Survival risk factors were analyzed using both univariate and multivariate regression models. Overall survival (OS) was calculated using Kaplan-Meier statistics. First-line treatment regimens were stratified into standard- and higher-intensity regimens, and based on whether they incorporated a proteasome inhibitor (PI). A total of 281 patients (median age, 55 years) were included. Immunodeficiency of any kind was identified in 144 patients (51%), and 99 patients (35%) had HIV-positive results. The 5-year OS for the entire cohort was 36% (95% confidence interval, 30%-42%). In multivariate analysis, inferior OS was associated with Epstein-Barr virus-negative lymphoma, poor performance status, advanced stage, and bone marrow involvement. In an independent univariate analysis, the international prognostic index was associated with OS outcomes. Neither immunosuppression nor HIV infection, specifically, influenced OS. Among patients treated with curative intent (n = 234), the overall response rate was 72%. Neither the intensity of the treatment regimen nor the inclusion of PIs in first-line therapy was associated with OS. In this large retrospective study of patients with PBL, we identified novel risk factors for survival. PBL remains a challenging disease with poor long-term outcomes.


Subject(s)
Epstein-Barr Virus Infections , HIV Infections , Plasmablastic Lymphoma , Humans , Middle Aged , Plasmablastic Lymphoma/pathology , Retrospective Studies , HIV Infections/complications , HIV Infections/drug therapy , Epstein-Barr Virus Infections/complications , Herpesvirus 4, Human , Prognosis
2.
Clin Case Rep ; 3(5): 319-24, 2015 May.
Article in English | MEDLINE | ID: mdl-25984313

ABSTRACT

Cryptococcosis is a potentially fatal fungal infection caused mainly by Cryptocococcus neoformans (CN) species and it rarely infects immunocompetent hosts. The outcomes are better only if the condition is suspected and diagnosed early and treatment is instituted.

SELECTION OF CITATIONS
SEARCH DETAIL